Aminolaevulinic acid (ALA)-induced photodynamic therapy in bladder cancer
| ISRCTN | ISRCTN93651553 |
|---|---|
| DOI | https://doi.org/10.1186/ISRCTN93651553 |
| Secondary identifying numbers | RBF 96XX9; N0497017886 |
- Submission date
- 23/01/2004
- Registration date
- 23/01/2004
- Last edited
- 18/10/2012
- Recruitment status
- Stopped
- Overall study status
- Stopped
- Condition category
- Cancer
Prospectively registered
Protocol
Statistical analysis plan
Results
Individual participant data
Record updated in last year
Plain English summary of protocol
Not provided at time of registration
Contact information
Dr M W Reed
Scientific
Scientific
University Department of Anaesthetics
Royal Hallamshire Hospital
Glossop Road
Sheffield
S10 2JF
United Kingdom
| Phone | +44 (0)114 271 1900 Ext 2102 |
|---|---|
| m.w.reed@sheffield.ac.uk |
Study information
| Study design | Randomised controlled trial |
|---|---|
| Primary study design | Interventional |
| Secondary study design | Randomised controlled trial |
| Study setting(s) | Not specified |
| Study type | Treatment |
| Scientific title | |
| Study objectives | Aims of the project: Prior determination of the optimum light and AminoLaevulinic Acid (ALA) parameters are a prerequisite for designing a successful treatment strategy, optimising the efficacy of ALA-induced PhotoDynamic Therapy (PDT) in the treatment of bladder cancer. The objectives of this proposal are therefore to: 1. Determine the optimal dose of ALA and the time required for maximal photosensitisation in bladder tumours 2. Perform in-vivo light dosimetry studies to achieve the optimal depth of PDT in bladder tumours 3. Determine the dosing parameters and methodology for a clinical trial of PDT for the treatment of early superficial bladder cancer and carcinoma in-situ in patients who have failed to respond to conventional treatment and are faced with the prospect of cystectomy. Ultimately, if the treatment proves successful, PDT may become the primary treatment modality for Carcinoma In Situ (CIS) and superficial bladder cancer. Although it will not be possible to undertake a clinical trial as part of this project it is hoped that it will be carried out subsequently using the data and expertise gained during this project. |
| Ethics approval(s) | No ethics information provided at time of registration |
| Health condition(s) or problem(s) studied | Cancer (neoplasms): Bladder (superficial) |
| Intervention | Patients will be accommodated in a side room with subdued light to minimise the risk of skin photosensitisation. Liver function tests will be performed 1 hour pre- and 24 hours post-operatively as there is a reported incidence of mild liver function test derangement following ALA administration. Patients will be randomised to one of seven groups: Group one: Control Group two: Intra-Bladder (IB) instillation 3% ALA solution one hour pre-operatively Group three: IB instillation 3% ALA solution four hours pre-operatively Group four: IB instillation 10% ALA solution one hour pre-operatively Group five: IB instillation 10% ALA solution four hours pre-operatively Group six: Oral administration 30 mg/kg ALA four hours pre-operatively Group seven: Oral administration 60 mg/kg ALA four hours pre-operatively ALA Dosing: Patients randomised to groups two to five will be catheterised one or four hours preoperatively and 50 ml of sterile 3% or 10% ALA solution will be instilled and the catheter clamped. Patients in groups six and seven will receive an oral dose of 30 or 60 mg/kg of ALA four hours pre-operatively. The oral dose has been chosen from previously published data. Processing of tissue samples: The time of removal of the resection specimen and histological assessment will be performed in the normal manner. Further small samples will be taken for Protoporphyrin IX (PpIX) analysis by fluorescence microscopy and High Performance Liquid Chromatography (HPLC). Further samples will micro-dissected into the different tissue components (namely mucosa, muscularis propria and tumour) and specific analysis of the level of PpIX in these components will be determined by Spectrophotometry (lS). Fluorescence microscopy will show the detailed microscopic distribution of the PpIX but is only a semi-quantitative technique, HPLC will determine the relative amounts of PpIX and profiles of other fluorescent porphyrins produced in the haem biosynthetic pathway and spectrophotometric analysis will give precise quantitative data on the level of PpIX in the different tissue components. Light dosimetry: Light dosimetry studies will be performed. Patient enrolment will be as described above, with patients about to undergo cystectomy being invited to participate in the study. 48 hours before surgery, patients will be given an appropriate dose of ALA (the time to light activation, dose and route of administration as determined in the phase 1 study). They will undergo flexible cystoscopy and the area of abnormality will be identified and biopsied. The bladder will then be distended with 100 ml sterile water. Light will be delivered at 514 nm (n = 4), or 630 nm (n = 4) at two doses, (100 and 200 J/cm^2) to adjacent areas of tumour and normal tissue in each patient. The treated area will be marked with indict ink. At surgery 48 hours later, the appropriate sections of the bladder will be assessed histologically for mucosal denudation, extent and depth of necrosis and inflammatory response in the treated area. |
| Intervention type | Drug |
| Pharmaceutical study type(s) | |
| Phase | Not Specified |
| Drug / device / biological / vaccine name(s) | Aminolaevulinic acid |
| Primary outcome measure | Potential patient and health service benefits |
| Secondary outcome measures | Not provided at time of registration |
| Overall study start date | 01/07/1996 |
| Completion date | 30/06/1997 |
| Reason abandoned (if study stopped) | Lack of resources |
Eligibility
| Participant type(s) | Patient |
|---|---|
| Age group | Adult |
| Sex | Not Specified |
| Target number of participants | 28 |
| Key inclusion criteria | 28 patients with carcinoma in situ and superficial invasive carcinoma of the bladder who have been advised to have cystectomy or TransUrethral Resection of Tumour (TURT) (respectively) will be invited to participate in the study and written informed consent obtained. |
| Key exclusion criteria | Not provided at time of registration |
| Date of first enrolment | 01/07/1996 |
| Date of final enrolment | 30/06/1997 |
Locations
Countries of recruitment
- England
- United Kingdom
Study participating centre
University Department of Anaesthetics
Sheffield
S10 2JF
United Kingdom
S10 2JF
United Kingdom
Sponsor information
NHS R&D Regional Programme Register - Department of Health (UK)
Government
Government
The Department of Health
Richmond House
79 Whitehall
London
SW1A 2NL
United Kingdom
| Phone | +44 (0)20 7307 2622 |
|---|---|
| dhmail@doh.gsi.org.uk | |
| Website | http://www.doh.gov.uk |
Funders
Funder type
Government
NHS Executive Trent (UK)
No information available
Results and Publications
| Intention to publish date | |
|---|---|
| Individual participant data (IPD) Intention to share | No |
| IPD sharing plan summary | Not provided at time of registration |
| Publication and dissemination plan | Not provided at time of registration |
| IPD sharing plan |
